



## ASX Announcement

### **BrainChip Holdings Ltd Quarter Update Appendix 4C & Quarterly Activities Report for the period ended 31 March 2021**

- 
- Cash Balance as at 31 March 2021 US\$20M
  - BrainChip begins Volume Production of Akida™ AI Processor
  - BrainChip added to the S&P/ASX 300 index and the All Ordinaries
  - Company Appoints Peter van der Made as Interim Chief Executive Officer
- 

**Sydney, Australia – 28 April 2021** – [BrainChip Holdings Ltd](#) (ASX: BRN), a leading provider of ultra-low power high performance AI technology, today provides the following update in conjunction with its Appendix 4C lodged for the quarter ending 31 March 2021.

The Company ended the March quarter with US\$20.0M in cash compared to US\$19.1M in the prior quarter. Cash inflows included receipts from customers of US\$1.12M and proceeds from the exercise of options of US\$3.0M related to the LDA Put Option Agreement and employee stock option exercises.

During the quarter, the Company had net cash outflows from operating activities of US\$3.8M compared to US\$2.7M in the prior quarter. The increase in outflows was due to a milestone payment of US\$2.25M to a major supplier in advance of wafer fabrication for the production version of the Akida device.

Subsequent to the end of the quarter, the Company's design and manufacturing partner, Socionext, released the engineering layout of the production version of the AKD1000 chip to Taiwan Semiconductor Manufacturing Company. Production units are expected to be available for testing in the 3<sup>rd</sup> Quarter.

Other developments during the March ended Quarter:

12 March: BrainChip to be added to S&P/ASX 300 Index and the All Ordinaries effective 22 March 2021.

16 March: The Company appointed Mr. Peter van der Made to the position of Interim Chief Executive Officer to replace Mr. Louis DiNardo who left the Company. The Board of Directors

continues to conduct a thorough search for a highly qualified and seasoned permanent replacement.

16 April: The Company announced that it had changed its ticker symbol on the US OTC Market to BRCHP in conjunction with submitting an application to upgrade its US listed stock to the OTCQX, the highest quality tier offered by OTC Marketplace for investor-focused, US and international companies traded on a qualified exchange. The Company anticipates receiving approval within the next few weeks.

BrainChip currently has entities in Perth Australia, Aliso Viejo California (United States), Toulouse France and Hyderabad India. The Company continues to maintain strict cost controls, as well as adhering to travel restrictions and precautionary measures related to the COVID-19 pandemic.

The Company will continue to update the market on material events and maintain monthly Podcasts designed to inform all constituents of the Company's progress and industry trends.

The Company has reported payments of US\$253,000 to related parties and their associates at item 6.1 of the accompanying Appendix 4C. These payments comprise directors' fees for Non-Executive Directors and salaries for Executive Directors.



**This announcement is authorised for release by the BRN Board of Directors.**

---

## About BrainChip Holdings Ltd (ASX: BRN)

BrainChip is a global technology company that is producing a groundbreaking neuromorphic processor that brings artificial intelligence to the edge in a way that is beyond the capabilities of other products. The chip is high performance, small, ultra-low power and enables a wide array of edge capabilities that include on-chip training, learning and inference. The event-based neural network processor is inspired by the spiking nature of the human brain and is implemented in an industry standard digital process. By mimicking brain processing BrainChip has pioneered a processing architecture, called Akida™, which is both scalable and flexible to address the requirements in edge devices. At the edge, sensor inputs are analyzed at the point of acquisition rather than through transmission via the cloud to a data center. Akida is designed to provide a complete ultra-low power and fast AI Edge Network for vision, audio, olfactory and smart transducer applications. The reduction in system latency provides faster response and a more power efficient system that can reduce the large carbon footprint of data centers.

---

Additional information is available at:

<https://www.brainchipinc.com>

[Investor Relations Contact: IR@brainchip.com](mailto:IR@brainchip.com)

Follow BrainChip on Twitter: [https://www.twitter.com/BrainChip\\_inc](https://www.twitter.com/BrainChip_inc)

Follow BrainChip on LinkedIn: <https://www.linkedin.com/company/7792006>

**Company contact:**

**Ken Scarince**

[IR@brainchip.com](mailto:IR@brainchip.com)

[kscarince@brainchip.com](mailto:kscarince@brainchip.com)

**+1 (626) 415-8848**

BrainChip Holdings Ltd

ACN 151 159 812

Level 12 225 George St Sydney NSW 2000

T: +61 2 9290 9606 | F: +61 2 9297 0664 | W: [www.brainchipinc.com](http://www.brainchipinc.com)

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

BrainChip Holdings Ltd

**ABN**

64 151 159 812

**Quarter ended ("current quarter")**

31 March 2021

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$US'000</b>	<b>Year to date (3 months) \$US'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	1,123	1,123
1.2 Payments for		
(a) research and development	(1,086)	(1,086)
(b) product manufacturing and operating costs *	(2,334)	(2,334)
(c) advertising and marketing	(450)	(450)
(d) leased assets	-	-
(e) staff costs	(504)	(504)
(f) administration and corporate costs	(578)	(578)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	10	10
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(3,819)</b>	<b>(3,819)</b>

\* \$2,250,000 relates to third party expenses associated with the Akida device development (could be at end of para 4.6)

<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-

Consolidated statement of cash flows		Current quarter \$US'000	Year to date (3 months) \$US'000
	(c) property, plant and equipment	(16)	(16)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(16)</b>	<b>(16)</b>
<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	3,031	3,031
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(21)	(421)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$US'000</b>	<b>Year to date (3 months) \$US'000</b>
3.9 Other (provide details if material)		
- Reduction in leases	(12)	(12)
- Funds payable to shareholders on exercise of options	1,707	1,707
<b>3.10 Net cash from / (used in) financing activities</b>	<b>4,705</b>	<b>4,705</b>

<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of period	19,136	19,136
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(3,819)	(3,819)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(16)	(16)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	4,705	4,705
4.5 Effect of movement in exchange rates on cash held	(14)	(14)
<b>4.6 Cash and cash equivalents at end of period</b>	<b>19,992</b>	<b>19,992</b>

<b>5. Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$US'000</b>	<b>Previous quarter \$US'000</b>
5.1 Bank balances	19,954	19,096
5.2 Call deposits	38	40
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
<b>5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>19,992</b>	<b>19,136</b>

<b>6. Payments to related parties of the entity and their associates</b>	<b>Current quarter \$US'000</b>
6.1 Aggregate amount of payments to related parties and their associates included in item 1	253
6.2 Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>	

<b>7. Financing facilities</b> <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	<b>Total facility amount at quarter end \$US'000</b>	<b>Amount drawn at quarter end \$US'000</b>
7.1 Loan facilities	412	412
7.2 Credit standby arrangements	23	-
7.3 Other (please specify)	-	-
7.4 <b>Total financing facilities</b>	435	412
7.5 <b>Unused financing facilities available at quarter end</b>		
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
<p>BrainChip SAS has a secured overdraft facility with Credit Agricole, France, to the value of 20,000 Euros which incurs interest at 8.02%.</p> <p>BrainChip Inc has a US\$412k Loan from the U.S. Govt under the CARES Act Paycheck Protection Program. This is an unsecured loan with an interest rate of 1% and maturity date of April 2022. The Company has applied for loan forgiveness prior to maturity.</p>		

<b>8. Estimated cash available for future operating activities</b>	<b>\$US'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	(3,819)
8.2 Cash and cash equivalents at quarter end (item 4.6)	19,992
8.3 Unused finance facilities available at quarter end (item 7.5)	23
8.4 Total available funding (item 8.2 + item 8.3)	20,015
8.5 <b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	5.2
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: n/a

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: n/a

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: n/a

*Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.*

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

28 April 2021

Date: .....

The Board of Directors

Authorised by: .....  
(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly



maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

For personal use only